Literature DB >> 23933140

Inhalable DNase I microparticles engineered with biologically active excipients.

Rihab Osman1, Khuloud T Al Jamal, Pei-Lee Kan, Gehanne Awad, Nahed Mortada, Abd-Elhameed El-Shamy, Oya Alpar.   

Abstract

Highly viscous mucus poses a big challenge for the delivery of particulates carrying therapeutics to patients with cystic fibrosis. In this study, surface modifying DNase I loaded particles using different excipients to achieve better lung deposition, higher enzyme stability or better biological activity had been exploited. For the purpose, controlled release microparticles (MP) were prepared by co-spray drying DNase I with the polymer poly-lactic-co-glycolic acid (PLGA) and the biocompatible lipid surfactant 1,2-dipalmitoyl-Sn-phosphatidyl choline (DPPC) using various hydrophilic excipients. The effect of the included modifiers on the particle morphology, size, zeta potential as well as enzyme encapsulation efficiency, biological activity and release had been evaluated. Powder aerosolisation performance and particle phagocytosis by murine macrophages were also investigated. The results showed that more than 80% of enzyme activity was recovered after MP preparation and that selected surface modifiers greatly increased the enzyme encapsulation efficiency. The particle morphology was greatly modified altering in turn the powders inhalation indices where dextran, ovalbumin and chitosan hydrochloride increased considerably the respirable fraction compared to the normal hydrophilic carriers lactose and PVP. Despite of the improved aerosolisation caused by chitosan hydrochloride, yet retardation of chitosan coated particles in artificial mucus samples discouraged its application. On the other hand, dextran and polyanions enhanced DNase I effect in reducing cystic fibrosis mucus viscosity. DPPC proved good ability to reduce particles phagocytic uptake even in the presence of the selected adjuvants. The prepared MP systems were biocompatible with lung epithelial cells. To conclude, controlled release DNase I loaded PLGA-MP with high inhalation indices and enhanced mucolytic activity on CF sputum could be obtained by surface modifying the particles with PGA or dextran.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; DNase I; Dextran; Leucine; Polyanions; Pulmonary

Mesh:

Substances:

Year:  2013        PMID: 23933140     DOI: 10.1016/j.pupt.2013.07.010

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  4 in total

Review 1.  Carrot cells: a pioneering platform for biopharmaceuticals production.

Authors:  Sergio Rosales-Mendoza; Marlene Anahí Tello-Olea
Journal:  Mol Biotechnol       Date:  2015-03       Impact factor: 2.695

2.  Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.

Authors:  Mohammed M Mehanna; Salma M Mohyeldin; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2019-11-22

Review 3.  Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis.

Authors:  Cecilia Velino; Francesca Carella; Alessio Adamiano; Maurizio Sanguinetti; Alberto Vitali; Daniele Catalucci; Francesca Bugli; Michele Iafisco
Journal:  Front Bioeng Biotechnol       Date:  2019-12-17

Review 4.  Polymers as Encapsulating Agents and Delivery Vehicles of Enzymes.

Authors:  Adejanildo da S Pereira; Camila P L Souza; Lidiane Moraes; Gizele C Fontes-Sant'Ana; Priscilla F F Amaral
Journal:  Polymers (Basel)       Date:  2021-11-23       Impact factor: 4.329

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.